Larvol Delta - BioPath-Holdings-Announces-Completion-of-First-Dose-Cohort-in-Phase-1-Clinical-Trial-Evaluating-BP1002-to-Treat-RefractoryRelapsed-Lymphoma-and-RefractoryRelapsed-Chronic-Lymphocytic-Leukemia-Patients

liposomal Bcl2 (BP1002) - Bio-Path

https://www.globenewswire.com/news-release/2024/01/10/2806973/0/en/Bio-Path-Holdings-Announces-Completion-of-First-Dose-Cohort-in-Phase-1-Clinical-Trial-Evaluating-BP1002-to-Treat-Refractory-Relapsed-Lymphoma-and-Refractory-Relapsed-Chronic-Lympho.html

Jan 10, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next